.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Merck
Cantor Fitzgerald
Colorcon
McKinsey
Accenture
Cerilliant
US Department of Justice
AstraZeneca

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,182,958

« Back to Dashboard

Which drugs does patent 7,182,958 protect, and when does it expire?


Patent 7,182,958 protects ADCIRCA and CIALIS and is included in two NDAs. There have been zero Paragraph IV challenges on Adcirca and Cialis

This patent has thirty-nine patent family members in twenty-eight countries.

Summary for Patent: 7,182,958

Title:.beta.-carboline pharmaceutical compositions
Abstract:Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use in treating sexual dysfunction, are disclosed.
Inventor(s): Oren; Peter L. (Fishers, IN), Anderson; Neil R. (West Lafayette, IN), Kral; Martha A. (Indianapolis, IN)
Assignee: Lilly Icos LLC. (Wilmington, DE)
Application Number:10/031,464
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use; Use; Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly Co
ADCIRCA
tadalafil
TABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► SubscribeY
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-004Jan 7, 2008RXYesNo► Subscribe► SubscribeY TREATMENT OF ERECTILE DYSFUNCTION
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► SubscribeY TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► SubscribeY TREATMENT OF ERECTILE DYSFUNCTION
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-002Nov 21, 2003RXYesNo► Subscribe► SubscribeY TREATMENT OF ERECTILE DYSFUNCTION
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-003Nov 21, 2003RXYesYes► Subscribe► SubscribeY TREATMENT OF ERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,182,958

PCT Information
PCT FiledApril 26, 2000PCT Application Number:PCT/US00/11130
PCT Publication Date:February 08, 2001PCT Publication Number: WO01/08686

Non-Orange Book Patents for Patent: 7,182,958

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,841,167 .beta.-carboline pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,182,958

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1200090► Subscribe
Portugal1200090► Subscribe
Poland199137► Subscribe
Poland353304► Subscribe
New Zealand516616► Subscribe
Norway321649► Subscribe
Norway20020532► Subscribe
MexicoPA02001196► Subscribe
South Korea20060093355► Subscribe
Japan2010163464► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Express Scripts
Queensland Health
Johnson and Johnson
Citi
Teva
Medtronic
AstraZeneca
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot